Diabetes

Novo Nordisk has submitted a supplemental application to the FDA to include data from the 2 phase 3b SWITCH trials in the prescribing information for insulin degludec (Tresiba), a once-daily basal insulin that provides a duration of action beyond 42 hours for patients with type 1 and type 2 diabetes.

The FDA has just approved the first automated insulin delivery device for patients 14 years and older with type 1 diabetes (T1D).

Only 12.8% of all experimental diabetes drugs transition to phase 3 trials.

Top news of the day from across the health care landscape.

Popular diabetes drug reduces the risk of cardiovascular complications.

Study finds greater risk of cardiovascular disease in some ethnicities with HIV.

Metformin found to impact metabolic pathways in type 2 diabetes.

Diabetes is a disease that affects a person's life each day by having a negative effect on quality of life and creating a financial burden for patients and families.

Fast-acting Conus geographus venom insulin may lead to fast-acting insulins.

A genetic modification prevented neuropathy in obese mice with diabetes.

Ointment shows promise preventing neuropathy.

Top news of the day from across the health care landscape.

Changes in the Rap1 gene associated with leptin resistance, which promotes obesity.

Onduo use technological advances to enhance management of diabetes.

Onduo will use new technology and professional care to improve the lives of patients with diabetes.

Canagliflozin and metformin hydrochloride extended release (Invokamet) improves blood glucose control in adults with type 2 diabetes.

Canagliflozin with extended release formulation of metformin improves blood glucose control in type 2 diabetes.

The FDA has just approved Janssen's Invokamet XR, a once-daily, fixed-dose combination of canagliflozin (Invokana) and extended-release metformin hydrochloride, for first-line treatment for type 2 diabetes in adults as an adjunct to diet and exercise.

Although venomous cone snails are sea-dwelling creatures, researchers have found a remarkable use for them on land.

New strategy helps slow kidney disease progression that can occur in diabetes.

Oral administration of insulin may be possible with Cholestosomes.

The FDA has extended the regulatory review period for Novo Nordisk's IDegLira, a potential once-daily fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for adults with type 2 diabetes.

Top news of the day from across the health care landscape.

Genetically engineered mice lacking a specific protein developed diabetes at a faster rate.

Antibiotics have been found to alter gut microbiomes, which increases the risk of type 1 diabetes.

Typically used to treat type 2 diabetes, metformin could slow heart disease development in patients with type 1 diabetes.

Pharmacists are much more likely to see prescriptions for sodium-glucose co-transporter 2 (SGLT2) inhibitors than obesity medications, recent prescription data reveal.

New research compares cardiovascular issues among patients with type 2 diabetes and psoriasis.

Drugs that treat diabetes are prescribed significantly more than antiobesity medications.

Omega-3 fatty acid supplements may help address the growing prevalence of type 2 diabetes mellitus and diabetic retinopathy.